Category: Capital Markets

Canbiola, Inc. (CANB) Announces ā€œ2017 Review ā€“ Update to Shareholdersā€

HICKSVILLE, NY / ACCESSWIRE / January 3, 2018 / Canbiola, Inc. (OTC PINK: CANB) is happy to provide this update to shareholders and review major events and accomplishments in 2017. Dear Shareholder, 2017 was a transition year as we transformed the company from a technology/software company to a company participating in the growing cannabis industry, with a focus on selling and developing products containing Cannabidiol (CBD) derived from industrial hemp. Here’s an overview of our proud accomplishments for 2017: Medical Advisory Board and Distributors: We added a number of medical professionals to our Advisory Board in addition to entering into distribution agreements with each. Read below our specific announcements on the five medical professionals added in 2017: Dr. Robert A. Kornfeld Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Dr. John P. Salerno Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Dr. Patrick M. Fratellone Joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Dr. Harry Benisatto joins Canbiola, Inc. (CANB) as Medical Advisor and Distributor Canbiola, Inc. (CANB) Announces Addition of Smita Ohri M.D. as Medical Advisor Manufacturing: We can proudly announce today that in the last quarter of 2017 we established a manufacturing agreement with a 3rd party manufacturer in the U.S. whereby we will be able to directly manufacture at manufacturers cost and white-label others’ products with no up-front fees due from the company....

Read More

Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

SHARE THIS POST Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders – – Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer – – Conference Call to be Held at 8:30 AM Tomorrow, January 4, 2018 – DEVON, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) —  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced that it will concentrate its focus on rare (meeting the US FDA designation of an orphan disease, affecting fewer than 200,000 people in the U.S.) and near-rare (affecting fewer than one million people in the U.S.) neurological and psychiatric (“neuropsychiatric”) disorders with high unmet medical needs. In 2018, the Company intends to develop ZYN002 in a pivotal Phase 2/3 program in Fragile X syndrome (FXS) and in Phase 2 programs in refractory epilepsies, including adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE) in pediatric and adolescent patients. Additionally, the Company plans to initiate Phase 2 development of ZYN001 in Tourette Syndrome by year end 2018. “The decision to concentrate on rare and near-rare neurological and psychiatric disorders is driven by a number of important factors, including the compelling ZYN002 clinical data seen to date in Fragile X syndrome and refractory focal epilepsy and by the opportunities for a more efficient and rapid development and regulatory approval process,” said...

Read More

Vitality Biopharma Introduces Cannabinoid Pharmaceutical VITA-100 as Prodrug of THC

SHARE THIS POST THC safety record and prior FDA approval propels Vitality’s prodrug as targeted treatment for pediatric IBD without drug psychoactivity LOS ANGELES, CA – (January 3, 2018) — Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today introduced its lead cannabinoid drug formulation VITA-100 as a non-psychoactive prodrug of THC. Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which enable targeted delivery of THC to the large intestine. THC has been previously reviewed and approved by the U.S. Food & Drug Administration (FDA) under the name dronabinol, and has been established as safe and effective for use with appetite stimulation and for treatment of nausea and vomiting. Vitality’s cannabosides could enable oral delivery of large concentrations of cannabinoids in order to provide therapeutic benefits while reducing or eliminating psychoactivity by limiting entry of THC into the bloodstream or brain. Vitality is focusing initial clinical development efforts on VITA-100, a proprietary THC cannabinoid drug formulation, and plans to complete a first-in-man clinical study in the first half of 2018. The treatment indications the Company plans to evaluate in Phase 2 trials include inflammatory bowel disease (IBD), irritable bowel syndrome, and narcotic bowel syndrome, a severe form...

Read More

Emerald Health Announces $15 Million Prospectus Sale; Concurrent Secondary Sale

SHARE THIS POST VICTORIA, British Columbia, Jan. 03, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald” or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 3,000,000 units of the Company (the “Units”) at a price of $5.00 per Unit for total gross proceeds of $15,000,000 (the “Offering”). The securities forming the Units will be qualified under a shelf prospectus supplement to be filed by Emerald prior to closing. Each Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the Investor to acquire one common share of the Company (a “Warrant Share”) at a price of $6.00 per Warrant Share for a period of 36 months following the closing of the Offering. In the event that the closing sale price of the Company’s common shares (the “Common Shares”) on the TSX Venture Exchange is greater than $8.00 per Common Share for a period of 10 consecutive trading days at any time after the closing of the Offering, the Company may accelerate the expiry date of the Warrants by giving notice to the Investor and in such case the Warrants will expire on the 30th day after the date on which such...

Read More

Cannabis Investing in 2018 ā€“ Our View

SHARE THIS POST January 2, 2018 – Looking back at cannabis stocks in 2017, the only theme that makes sense is “FOMA” (Fear of Missing Out). By mid-December, more than $3.2 billion of capitalization flowed into the cannabis sector, up 191% over the $1.1 billion invested in the same period 2016. That $3.2 billion translated into 388 transactions (as opposed to 328 in 2016), with an average deal size of $8.3 million (up from $3.4 million in 2016). Of that, $2.6 million (306 transactions) were equity and $574 million (82 transactions) were debt. The public sector accounted for $2.7 billion raised while private companies raised $533 million.[1] So what is driving the surge of investment capital flowing into cannabis? We would argue that it isn’t fundamentals. On the other hand, investors are frothy, and the sentiment has been sheer speculation. Take the Cultivation and Retail segment. We reviewed 21 companies (see table below) to find that in 2017, they ended the year with $18.7 billion in capitalization, with an average increase in valuation of 167% over the year. The combined revenues for the businesses (trailing 12-months) was $193 million. That translates into a surreal price-to-sales ratio for the combined segment of 97. On an earnings basis, only 2 of the 21 was positive. Combined, the segment lost $193 million for the period. Turning to book value, we found that...

Read More

Alliance Growers to Acquire Quebec Late State ACMPR Applicant

January 2, 2018 – Vancouver, B.C. – Alliance Growers Corp. (CSE: ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to report that it has entered into an exclusive agreement to acquire a late stage licensed producer applicant, Biotech Canna, to become a licensed producer under Health Canada’s access to cannabis for medical purposes regulations (“ACMPR”) in Quebec.  Alliance Growers will supply financing and resources to build out the medical marijuana facility in preparation for the inspection required to obtain a growing license. Once Health Canada is satisfied with a successful crop, Alliance Growers will be granted its distribution license. This is a key acquisition for Alliance Growers and its shareholders, as it allows the company an opportunity to become a licensed producer in the province of Quebec and gain an in-road to provide tissue culture plantlets to all licensed producers in Quebec. There are several key points of value that are unique and advantageous to a Quebec license that include: – 20% of Canada population is in Quebec – Only 2 licenses have been approved in Quebec with only 1 producing (Hydropocathary). – Quebec government has always looked to attain 25% of whatever Canada’s intentions are with business. They have publicly stated they want Health Canada to process all the licenses- 16 Applications – in Quebec and have the applications approved swiftly. – Quebec will...

Read More